Phase II Study of Erlotinib (Tarceva) in Patients With Advanced Pancreatic Adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 30 Aug 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.